Denosumab More Cost Effective v Zoledronic Acid in Multiple Myeloma
Noopur Raje, MD of Massachusetts General Hospital Cancer Center outlines how the recently released economic analysis of Denosumab v. Zoledronic Acid found that Denosumab was overall more cost effectiv... Author: Lymphoma-Myeloma-Conference Added: 11/06/2017 (Source: Oncology Tube)
Source: Oncology Tube - November 7, 2017 Category: Cancer & Oncology Source Type: podcasts

Economic Analysis Denosumab v Zoledronic Acid in Multiple Myeloma
Noopur Raje, MD of Massachusetts General Hospital Cancer Center discusses her findings in which Denosumab is favored in newly diagnosed multiple myeloma patients from a recent economic analysis of Den... Author: Lymphoma-Myeloma-Conference Added: 11/06/2017 (Source: Oncology Tube)
Source: Oncology Tube - November 6, 2017 Category: Cancer & Oncology Source Type: podcasts

ASCO 2017- Denosumab compared with zoledronic acid on renal function in the treatment of myeloma bone disease
Impact of denosumab compared with zoledronic acid on renal function in the treatment of myeloma bone disease Author: InternationalMyelomaFoundation Added: 08/15/2017 (Source: Oncology Tube)
Source: Oncology Tube - August 15, 2017 Category: Cancer & Oncology Source Type: podcasts

Bone metastases: Role of zoledronic acid, denosumab and other strategies
In this presentation from the 21st Annual Perspectives in Thoracic Oncology, Dr. Vera Hirsh discusses the role of zoledronic acid, denosumab, and other strategies in the treatment of bone metastases.... Author: imedex Added: 05/05/2017 (Source: Oncology Tube)
Source: Oncology Tube - May 5, 2017 Category: Cancer & Oncology Source Type: podcasts

Biosimilar therapy for breast cancer, zoledronic acid for bone metastases, the future of Obamacare under Donald Trump, and more
Editors’ Summary by Phil B. Fontanarosa, MD, MBA, Executive Editor of JAMA, the Journal of the American Medical Association, for the January 3, 2017 issue (Source: JAMA: This Week's Audio Commentary)
Source: JAMA: This Week's Audio Commentary - January 3, 2017 Category: Journals (General) Authors: JAMA, the Journal of the American Medical Association, and The JAMA Network Source Type: podcasts

Is it reasonable to take Zometa for longer than two years?
In this week’s video, Dr. Durie discusses how to safely use the bisphosphonate Zometa to control myeloma bone disease. BOTTOM LINE: Discontinue Zometa after two years unless bone disease is a m... Author: MultipleMyeloma Added: 05/27/2016 (Source: Oncology Tube)
Source: Oncology Tube - May 27, 2016 Category: Cancer & Oncology Source Type: podcasts

Zoledronate or Denosumab for Lung Cancer with Bone Metastases
Dr. Benjamin Levy, Mount Sinai Health Systems, compares zoledronic acid and denosumab, two agents used for treatment of bone metastases in lung cancer. http://cancergrace.org/lung...... Author: cancergrace Added: 04/01/2016 (Source: Oncology Tube)
Source: Oncology Tube - April 1, 2016 Category: Cancer & Oncology Source Type: podcasts